Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug-coated stent looks promising in trial:

This article was originally published in Clinica

Executive Summary

Biocompatibles International's coronary stent coated with a drug made by Abbott Laboratories looks to be a promising way of preventing restenosis, according to early data from a preclinical trial. The US study involving pigs show that the drug-coated devices lead to a 43% reduction in new tissue growth, with related improvement in internal vessel size and no significant injury or inflammation within the treated artery. Biocompatibles of Farnham, UK, is investigating the use of a number of anti-restenosis pharmaceuticals for use on its stent.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel